Total Hip Arthroplasty Readmission Influenced by Behavioral Comorbidities

Share this content:
There was a strong independent association between obesity and RTT.
There was a strong independent association between obesity and RTT.

HealthDay News — For patients undergoing total hip arthroplasty (THA), factors associated with 30-day readmission resulting in return to theater (RTT) include comorbidities likely to affect patient behavior, according to a study published online in JAMA Surgery.

Adam M. Ali, BMBCh, from St. Mary's Hospital in London, and colleagues examined the effect of patient-related factors on 30-day readmission risk in all acute National Health Service hospitals in England for all patients receiving primary THA from 2006-2015. A total of 514,455 procedures were recorded.

The researchers found that 5.9%, 3.2%, and 0.8% of the procedures resulted in all-cause readmissions, surgical readmissions, and RTT readmissions, respectively; more than half (54.1%) of readmissions were for surgical causes. 

The highest odds ratios [OR] of RTT were seen for comorbidities that were likely to impact patient behavior, including drug abuse, psychoses, dementia, and depression (OR 2.22, 1.83, 1.57, and 1.52, respectively). There was a strong independent association between obesity and RTT (OR 1.46), with a population attributable fraction of 3.4%. Return to theater in the index episode correlated with significantly increased risk of RTT readmission (OR 5.35).

"Many patient-related risk factors for surgical and RTT readmission differ from those for all-cause readmission despite the latter being the only measure in widespread use," the authors write. "Clinicians and policy makers should consider these alternative readmission metrics in strategies for risk reduction and cost savings."

Reference

Ali AM, Loeffler MD, AAylin P, Bottle A. Factors associated with 30-day readmission after primary total hip arthroplasty: analysis of 514,455 procedures in the UK national health service [published online October 4, 2017]. JAMA Surg. doi:10.1001/jamasurg.2017.3949



You must be a registered member of Rheumatology Advisor to post a comment.